Latest On Bayer Aktiengesellschaft (BAYZF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-04-29 05:57 EST | Dividend | A dividend of $0.11 has been announced on Feb 2, 2024. It will be paid May 2, 2024 with an ex-dividend date of Apr 29, 2024. | Neutral |  |
| 2023-05-22 01:30 EST | News | Bayer, Orion begin phase 3 trial of Nubeqa to expand prostate cancer indication | N/A | |
| 2023-05-22 01:29 EST | News | Delaware court finds in favor of Bayer in talc disagreement with Merck | N/A | |
| 2023-05-22 01:29 EST | News | Bayer to invest ~€60M in Ukrainian corn seed production site | N/A | |
| 2023-05-22 01:27 EST | News | Activist Bluebell steps up pressure for Bayer breakup, supervisory board changes - report | N/A | |
| 2023-05-22 01:26 EST | News | Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children | N/A | |
| 2023-05-22 01:26 EST | News | Bayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free' | N/A | |
| 2023-05-22 01:25 EST | News | Bayer AG Non-GAAP EPS of €2.95, revenue of €14.39B; targets outlook at lower end of guidance | N/A | |
| 2023-05-22 01:25 EST | News | Bayer Q1 sales dips as crop, pharma segments decline; glyphosate prices weigh on outlook | N/A | |
| 2023-05-22 01:24 EST | News | Bayer AG (BAYZF) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-22 01:24 EST | News | Bayer's stroke prevention drug asundexian gets 2nd FDA fast track status | N/A | |
| 2023-05-22 01:24 EST | News | Cancer-focused Boundless Bio closes $100M funding led by Bayer, RA Capital | N/A | |
| 2023-05-22 01:23 EST | News | Bayer Aktiengesellschaft 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-22 01:23 EST | News | Bayer's kidney disease drug Kerendia gets Chinese regulator nod for expanded use | N/A | |
| 2023-05-02 05:56 EST | Dividend | A dividend of $2.4 has been announced on Mar 2, 2023. It will be paid May 4, 2023 with an ex-dividend date of May 2, 2023. | Neutral | |
| 2023-04-26 11:46 EST | News | EU publishes proposed reforms for pharma industry | N/A | |
| 2023-02-28 12:20 EST | News | Bayer AG Non-GAAP EPS of €1.35, revenue of €12B | N/A | |
| 2022-09-13 20:33 EST | News | Bayer starts executive search to replace CEO Baumann – Bloomberg | N/A | |
| 2022-09-03 01:02 EST | News | Bayer in $40M settlement over allegations related to three drugs | N/A | |
| 2022-05-03 23:22 EST | News | Bayer granted FDA’s priority review for label expansion of prostate cancer therapy | N/A | |
| 2022-05-02 05:55 EST | Dividend | A dividend of $2 has been announced on Mar 2, 2022. It will be paid May 4, 2022 with an ex-dividend date of May 2, 2022. | Neutral | |
| 2022-03-09 15:41 EST | News | Bayer files for expanded use of prostate cancer drug Nubeqa in US, EU | N/A | |
| 2022-02-28 22:41 EST | News | Bayer Q4 Earnings Preview | N/A | |
| 2022-02-19 03:03 EST | News | Bayer raises peak sales estimate for prostate cancer drug after positive phase 3 data | N/A | |
| 2022-02-10 18:49 EST | News | Bayer's asundexian gets FDA fast track status for stroke program | N/A | |
| 2022-02-04 12:57 EST | News | Evotec regains rights to eliapixant after Bayer ends development; Evotec shares fall | N/A | |
| 2021-12-07 01:34 EST | News | Recursion expands collaboration with Bayer on fibrosis research | N/A | |
| 2021-08-05 16:58 EST | News | Bayer AG reports Q2 results | N/A | |
| 2021-07-22 11:00 EST | News | Bayer expands oncology portfolio with a deal to acquire Noria and PSMA Therapeutics | N/A | |
| 2021-04-28 05:57 EST | Dividend | A dividend of $2 has been announced on Mar 12, 2021. It will be paid Apr 30, 2021 with an ex-dividend date of Apr 28, 2021. | Neutral | |
| 2021-02-26 21:08 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-01 23:35 EST | News | CureVac ropes in Bayer to boost COVID-19 vaccine production | N/A | |
| 2021-01-13 21:13 EST | News | Bayer's blockbuster drugs will not bridge revenue gap led by expired patents: Pharma head | N/A | |
| 2021-01-12 16:14 EST | News | FDA accepts Bayer's finerenone application for chronic kidney disease and type 2 diabetes | N/A | |
| 2021-01-09 01:02 EST | News | FDA approves Bayer's application to add overall survival benefit to its Nubeqa prescription information | N/A | |
| 2020-12-22 11:36 EST | News | Veracyte and Bayer collaborate in precision oncology; shares jump +17% | N/A | |
| 2020-12-21 18:06 EST | News | Wuxi Biologics acquires drug substance facility from Bayer | N/A | |
| 2020-12-07 15:14 EST | News | Bayer, Atara inks licensing pact for T-cell therapies for solid tumors | N/A | |
| 2020-11-26 22:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 21:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-03 14:31 EST | News | Bayer AG reports Q3 results | N/A | |
| 2020-09-26 14:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 22:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-05 01:55 EST | News | Bayer AG EPS beats by €0.08, misses on revenue | N/A | |
| 2020-07-30 18:28 EST | Financials | Company financials have been released. | Neutral | |
About Bayer Aktiengesellschaft (BAYZF):
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
General
- Name Bayer Aktiengesellschaft
- Symbol BAYZF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 95,955
- Fiscal Year EndDecember
- Web URLhttp://www.bayer.com
Valuation
- Trailing PE 8.63
- Forward PE 9.12
- Price/Sales (Trailing 12 Mt.) 1.25
- Price/Book (Most Recent Quarter) 1.7
- Enterprise Value Revenue 2.34
- Enterprise Value EBITDA 10.06
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -25%
- Return on Assets 4%
- Return on Equity -40%
- Earnings Per Share $7.38
- Revenue Per Share $0
- Gross Profit 25.67 billion
- Quarterly Earnings Growth -7%
ESG Rating
Highlights
- Market Capitalization 62.14 billion
- PEG Ratio 4.91
- Book Value Per Share $59.72
Share Statistics
- Shares Outstanding 982.42 million
- Shares Float 982.42 million
- % Held by Insiders <1%
- % Held by Institutions 42.75%
Technicals
- Beta 1.33
- 52 Week High $84.49
- 52 Week Low $43.94
- 50 Day Moving Average 63.81
- 200 Day Moving Average 59.85
Dividends
- Forward Annual Dividend Rate $2.4
- Forward Annual Dividend Yield 3.79%
- Dividend Date N/A
- ExDividend Date 2021-04-28
- Dividend Per Share $3.26
- Dividend Yield 0%
Bayer Aktiengesellschaft (BAYZF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Bayer Aktiengesellschaft (BAYZF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.37 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.48 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$9.19 | $0.44 | -2189.36% |
| 2020-03-31 | 2020-06-30 | $12.85 billion | -$11.00 | $2.64 | -516.76% |
| 2019-12-31 | 2020-03-31 | $10.75 billion | $1.53 | $1.25 | 22.54% |
| 2019-09-30 | 2019-12-31 | $9.83 billion | -$0.05 | $1.17 | -104.2% |
| 2019-06-30 | 2019-09-30 | $13.05 billion | $1.10 | $1.83 | -39.98% |
| 2019-03-31 | 2019-06-30 | $13.02 billion | $0.36 | $2.66 | -86.3% |
| 2018-12-31 | 2019-03-31 | $11.06 billion | $1.29 | $2.11 | -38.86% |
| 2018-09-30 | 2018-12-31 | $11.47 billion | -$4.63 | $0.97 | -577.8% |
| 2018-06-30 | 2018-09-30 | $11.03 billion | $3.32 | $1.44 | 130.57% |
| 2018-03-31 | 2018-05-03 | $11.24 billion | $2.24 | $2.03 | 10.34% |
| 2017-12-31 | 2018-03-31 | $10.32 billion | $2.75 | $1.15 | 138.91% |
| 2017-09-30 | 2017-12-31 | $1 billion | $0.95 | $1.47 | -35.41% |
| 2017-06-30 | 2017-09-30 | $3.97 billion | $0.62 | $1.76 | -64.75% |
| 2017-03-31 | 2017-06-30 | $13.24 billion | $1.09 | $2.30 | -52.51% |
| 2016-12-31 | 2017-03-31 | $11.82 billion | $2.09 | $1.20 | 74.33% |
| 2016-09-30 | 2016-12-31 | $0.65 | $1.62 | -59.94% | |
| 2016-06-30 | 2016-09-30 | $1.16 | $1.98 | -41.63% | |
| 2016-03-31 | 2016-06-30 | $1.21 | $2.18 | -44.66% | |
| 2015-12-31 | 2016-03-31 | $2.01 | $1.26 | 59.69% | |
| 2015-09-30 | 2015-12-31 | $0.82 | $1.47 | -44.52% | |
| 2015-06-30 | 2015-09-30 | $1.33 | $1.85 | -27.92% | |
| 2015-03-31 | 2015-06-30 | $1.53 | $2.16 | -29.29% | |
| 2014-12-31 | 2015-03-31 | $1.66 | $1.21 | 36.99% | |
| 2014-09-30 | 2014-12-31 | $0.31 | $1.27 | -75.83% | |
| 2014-06-30 | 2014-09-30 | $1.22 | |||
| 2014-03-31 | 2014-06-30 | $1.51 | |||
| 2013-12-31 | 2014-03-31 | $2.33 | |||
| 2013-09-30 | 2013-12-31 | $0.76 | |||
| 2013-06-30 | 2013-09-30 | $1.20 | |||
| 2013-03-31 | 2013-06-30 | $1.32 | |||
| 2012-12-31 | 2013-03-31 | $1.79 | |||
| 2012-09-30 | 2012-12-31 | $0.58 | |||
| 2012-06-30 | 2012-09-30 | $0.80 | |||
| 2012-03-31 | 2012-06-30 | $0.74 | |||
| 2011-12-31 | 2012-03-31 | $1.68 | |||
| 2011-09-30 | 2011-12-31 | $0.62 | |||
| 2011-06-30 | 2011-09-30 | $1.04 | |||
| 2011-03-31 | 2011-06-30 | $1.31 | |||
| 2010-12-31 | 2011-03-31 | $1.17 | |||
| 2010-09-30 | 2010-12-31 | -$0.24 | |||
| 2010-06-30 | 2010-06-30 | $0.79 | |||
| 2010-03-31 | 2010-03-31 | $1.14 | |||
| 2009-09-30 | 2009-09-30 | $0.42 | |||
| 2009-06-30 | 2009-06-30 | $0.90 | |||
| 2009-03-31 | 2009-03-31 | $0.70 | |||
| 2008-12-31 | 2008-12-31 | $0.34 | |||
| 2008-09-30 | 2008-09-30 | $0.52 | |||
| 2008-06-30 | 2008-06-30 | $1.07 | |||
| 2008-03-31 | 2008-03-31 | $1.36 | |||
| 2007-12-31 | 2007-12-31 | $0.16 | |||
| 2007-09-30 | 2007-09-30 | $1.97 | |||
| 2007-06-30 | 2007-06-30 | $1.10 | |||
| 2007-03-31 | 2007-03-31 | $4.43 | |||
| 2006-12-31 | 2006-12-31 | $0.54 |
Bayer Aktiengesellschaft (BAYZF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 1.3 billion | 1.41 billion |
| Income Before Tax | N/A | N/A | N/A | 1.85 billion | 18 million |
| Selling General Administrative | N/A | N/A | N/A | 3.84 billion | 4.05 billion |
| Gross Profit | N/A | N/A | N/A | 8.19 billion | 5.88 billion |
| Ebit | N/A | N/A | N/A | 3.8 billion | 396 million |
| Operating Income | N/A | N/A | N/A | 2.5 billion | 396 million |
| Income Tax Expense | 987 million | -1.71 billion | -1.45 billion | 479 million | 45 million |
| Total Revenue | N/A | N/A | N/A | 12.85 billion | 10.75 billion |
| Cost of Revenue | N/A | N/A | N/A | 4.66 billion | 4.88 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -378 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | 1.37 billion | -27 million |
| Net Income Applicable to Common Shares | 308 million | -2.74 billion | -9.55 billion | 1.49 billion | 1.41 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -598 million | -605 million | -281 million |
| Change to Liabilities | 559 million | -184 million | -1.07 billion | 777 million | 409 million |
| Total Cash Flow from Investing Activities | -2.86 billion | -421 million | -598 million | 35 million | -239 million |
| Net Borrowings | 3.1 billion | 2.07 billion | 232 million | -3.95 billion | -707 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -4.47 billion | -1.02 billion |
| Change to Operating Activities | -1.04 billion | 11.63 billion | -373 million | 1.78 billion | -1.61 billion |
| Change in Cash | N/A | N/A | -791 million | -1.23 billion | 1.03 billion |
| Total Cash from Operating Activities | 1.97 billion | 2.41 billion | -229 million | 3.25 billion | 2.28 billion |
| Depreciation | N/A | N/A | 1.28 billion | 2.07 billion | 1.04 billion |
| Other Cash Flow from Investing Activities | 39 million | 14 million | 23 million | 39 million | 14 million |
| Change to Inventory | N/A | N/A | 396 million | -399 million | -317 million |
| Change to Account Receivables | N/A | N/A | N/A | 58 million | 2.18 billion |
| Other Cash Flow from Financing Activities | -220 million | -441 million | -196 million | -525 million | -304 million |
| Change to Net Income | 2.36 billion | -1.36 billion | 1.08 billion | -2.46 billion | -448 million |
| Capital Expenditures | N/A | N/A | 391 million | 1.07 billion | 729 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 76.69 billion | 78.74 billion |
| Total Stockholder Equity | N/A | N/A | N/A | 48.61 billion | 47.34 billion |
| Other Current Liabilities | 22.48 billion | 22.07 billion | N/A | 8.07 billion | 14.61 billion |
| Total Assets | N/A | N/A | N/A | 125.47 billion | 126.26 billion |
| Common Stock | 2.52 billion | 2.52 billion | 2.52 billion | 2.52 billion | 2.52 billion |
| Other Current Assets | 113 million | 43 million | N/A | N/A | 1.14 billion |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | 16.42 billion | 17.06 billion | 17.31 billion | 17.56 billion | 18.61 billion |
| Other Assets | 5.52 billion | 6.03 billion | 4.86 billion | 4.38 billion | 5.33 billion |
| Cash | N/A | N/A | N/A | 2.29 billion | 3.19 billion |
| Total Current Liabilities | 36.73 billion | 35.79 billion | N/A | 22.32 billion | 23.22 billion |
| Other Stockholder Equity | 28.01 billion | 28.81 billion | 33.19 billion | 46.09 billion | 44.82 billion |
| Property, Plant & Equipment | 11.71 billion | 11.5 billion | 11.85 billion | 12.1 billion | 12.48 billion |
| Total Current Assets | 35.66 billion | 39.34 billion | N/A | 33 billion | 32.56 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 2.06 billion |
| Net Tangible Assets | -31.59 billion | -29.25 billion | -36.48 billion | -25.29 billion | -26.5 billion |
| Short Term Investments | N/A | N/A | N/A | 2.76 billion | 2.33 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | 36.91 billion |
| Inventory | 10.96 billion | 10.45 billion | N/A | 10.01 billion | 10.77 billion |
| Accounts Payable | 5.68 billion | 5.46 billion | N/A | 5.33 billion | 6.43 billion |
Bayer Aktiengesellschaft (BAYZF) Chart:
Bayer Aktiengesellschaft (BAYZF) News:
Below you will find a list of latest news for Bayer Aktiengesellschaft (BAYZF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bayer Aktiengesellschaft (BAYZF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Bayer Aktiengesellschaft (BAYZF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|